Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial
Authors
Morgan, Robert DavidClamp, Andrew R
White, Daniel J
Price, Marcus
Burghel, G. J.
Ryder, W. D. J.
Mahmood, Reem D
Murphy, Alexander D
Hasan, Jurjees
Mitchell, Claire L
Salih, Zena
Wheeler, Chelsey
Buckley, Emma
Truelove, Joanna
King, G.
Ainaoui, Y.
Bhaskar, S. S.
Shaw, J.
Evans, D. G. R.
Kilerci, Bedirhan
Pearce, Simon P
Brady, Ged
Dive, Caroline
O'Connor, James P B
Wallace, A. J.
Rothwell, Dominic G
Edmondson, Richard J
Jayson, Gordon C
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester,Issue Date
2023
Metadata
Show full item recordAbstract
Purpose: A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of PARPi was unknown. Patients and methods: Phase II trial with two entry points (EP1, EP2). Patients were recruited prior to rechallenge platinum. Patients with relapsed, gBRCAm-HGSOC were enrolled at EP1 if they were PARPi-naïve. Patients enrolled at EP2 had received their first course of olaparib prior to trial entry. EP1 patients were retreated with olaparib after RECIST complete/partial response (CR/PR) to platinum. EP2 patients were retreated with olaparib ± cediranib after RECIST CR/PR/stable disease to platinum and according to the platinum-free interval. Co-primary outcomes were the proportion of patients who received a second course of olaparib and the proportion who received olaparib retreatment for ≥6 months. Functional homologous recombination deficiency (HRD), somatic copy-number alteration (SCNA), and BRCAm reversions were investigated in tumor and liquid biopsies. Results: Twenty-seven patients were treated (EP1 = 17, EP2 = 10), and 19 were evaluable. Twelve patients (63%) received a second course of olaparib and 4 received olaparib retreatment for ≥6 months. Common grade ≥2 adverse events during olaparib retreatment were anemia, nausea, and fatigue. No cases of MDS/AML occurred. Mean duration of olaparib treatment and retreatment differed (12.1 months vs. 4.4 months; P < 0.001). Functional HRD and SCNA did not predict PFS. A BRCA2 reversion mutation was detected in a post-olaparib liquid biopsy. Conclusions: A second course of olaparib can be safely administered to women with gBRCAm-HGSOC but is only modestly efficacious. See related commentary by Gonzalez-Ochoa and Oza, p. 2563.Citation
Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, et al. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial. Clinical Cancer Research. 2023 Jul;29(14):2602-11. PubMed PMID: WOS:001043746600001.Journal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-22-3282PubMed ID
36799931Additional Links
https://dx.doi.org/10.1158/1078-0432.CCR-22-3282Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-22-3282
Scopus Count
Collections
Related articles
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
- Authors: Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U
- Issue date: 2016 Nov
- EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
- Authors: Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM
- Issue date: 2020 Aug 15
- Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
- Authors: Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E
- Issue date: 2022 Mar
- Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
- Authors: Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C
- Issue date: 2022 Sep
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
- Authors: Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA
- Issue date: 2019 Apr 1